GlassScriptPhysician profile
Tyler Alan Webb
NPI 1770718108
$23,222.50
in general payments reported to CMS, 2019-2025
59 companies · $2,276 in 2025
The $2,276 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,919 · 2020: $4,997 · 2021: $2,000 · 2022: $2,372 · 2023: $2,414 · 2024: $2,244 · 2025: $2,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,898 · Education: $35.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,898.32 |
| Education | $35.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $8,859.74 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $2,962.22 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Allergan, INC. | $955.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $946.83 | 2019-2025 | |
| Pfizer INC. | $934.58 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $867.33 | 2019-2022 | |
| Genzyme Corporation | $543.30 | 2019-2023 | |
| Biogen, INC. | $478.11 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Lundbeck LLC | $374.37 | 2021-2025 | Vyepti, Rexulti |
| Sunovion Pharmaceuticals INC. | $372.75 | 2019-2022 | |
| Argenx US, INC. | $359.96 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $348.53 | 2019-2025 | Ajovy, Austedo Xr |
| Acadia Pharmaceuticals INC | $328.30 | 2020-2023 | Nuplazid |
| Celgene Corporation | $324.91 | 2020-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $302.62 | 2019-2024 | Ultomiris |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.